Omnaris Launch Delayed While Altana Sniffs Out Marketing Partner
Executive Summary
Altana will need to secure a marketing agreement with an outside partner before introducing its newly approved allergic rhinitis treatment Omnaris (ciclesonide nasal spray), the company said
You may also be interested in...
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.
Altana Omnaris Adrenal Function Assessment Was “Not Ideal,” FDA Says
Study design deficiencies impeded Altana's attempt to distinguish Omnaris (ciclesonide) from other nasal corticosteroids as having less potential to suppress the cortisol system and adrenal function